ArticleMetabolomics : Official journal of the Metabolomic Society2026
Metabolomic signature reveals dysregulated lipoprotein profile in m.3243A>G carriers: a case-control study.
Article in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe pathogenic mitochondrial gene variant m.3243A>G disrupts oxidative phosphorylation and is associated with insulin resistance, both of which may be linked to unfavorable lipid metabolism. However, the metabolic alterations in m.3243A>G carriers, including what differentiates those with and without diabetes, remain incompletely understood.
objectivesTo investigate metabolomic profiles in fasting serum and urine samples from m.3243A>G carriers compared to healthy controls.
methodsMetabolomic profiling of serum and urine samples using nuclear magnetic resonance-based metabolomics in m.3243A>G carriers (n = 28) was compared to healthy controls matched for age and sex. Additionally, profiles from m.3243A>G carriers with diabetes (n = 16) were compared with carriers without diabetes (n = 12) to identify potential metabolites associated with the presence of diabetes.
resultsTwenty-five metabolites in serum and 16 in urine were identified as metabolites separating m.3243A>G carriers from healthy controls. The m.3243A>G carriers presented with increased triglycerides across lipoprotein particles and altered very-low-density lipoprotein concentrations and composition. In addition, there were alterations in metabolites from a number of metabolic pathways, including glycolysis, the tricarboxylic acid cycle, glutathione, one-carbon, and nucleotide metabolism. A three metabolite-urine signature (uracil, hypoxanthine, and 1-methylnicotinamide) demonstrated discriminating potential between m.3243A>G carriers and controls in exploratory machine learning analyses (area under the curve values 0.94-0.99 and cross-validation prediction of 0.81-0.93). Among m.3243A>G carriers, branched-chain amino acids were higher in individuals with diabetes compared with carriers without diabetes.
conclusionDysregulated lipoprotein metabolism represents a significant metabolic fingerprint of m.3243A>G carriers. Furthermore, higher levels of branched-chain amino acids may be associated with the presence of diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.